

Company Overview

Khiron Life Sciences is a Latin American Cannabis Company with Global Growth with its core operations in Colombia. Khiron combines leading international scientific expertise, agricultural advantages and branded product market entrance experience to address the unmet medical needs in a market of over 620 million people in LatAm.

Khiron Life Sciences Enters Into \$20 Million Bought Deal Equity Financing

Feb 6 2019, 7:31 AM EST

Transformative Joint Venture Between Dixie Brands and Khiron Life Sciences Brings a Portfolio of Highly Recognized Cannabis-Infused Products to Latin America and Khiron's Kuida® Cosmeceutical Brand to the Federally legal U.S. CBD Cosmetic Market

Jan 30 2019, 8:23 AM EST

Khiron Life Sciences Signs Binding LOI to Acquire 100% of NettaGrowth, Securing the First Medical THC and CBD Cannabis Licence and Cultivation Capacity in Uruguay, and Entry to the Brazilian Market

Jan 25 2019, 9:17 AM EST

Stock Overview

Symbol	KHRN
Exchange	TSXV
Market Cap	232.09m
Last Price	\$3.05
52-Week	\$0.87 - \$3.13

02/15/2019 03:59 PM EST

Investor Relations

Chris Naprawa
President
T: +1 416-705-1144
investors@khiron.ca

Management Team

Alvaro Torres

Chief Executive Officer and Director

Chris Naprawa

President

Darren Collins

Chief Financial Officer

Juan Diego Alvarez

Vice President of Regulations

Andres Galofre

Vice President of Commercial

Matt Murphy

Vice President of Compliance

Maria-Fernanda Arboleda MD

Medical Director

Jairo Espinoza

Vice President of Medical Affairs

Khiron Life Sciences Corp.

100 King Street West
Suite 1600
Toronto, Ontario M5X 1A9
Canada

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.